LentiGlobin BB305

· Genetix Biotherapeutics Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LentiGlobin BB305, covering 2023-12-29 to 2023-12-29. Get the full timeline:

Most recent: Clinical Trial Update: A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia [Phase 3]

See pricing